Skip to main content

Animations

MJFF Publications

4271 - 4280 of 9033 Results
Title
Year
  • Year
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2021
  • 2022
  • 2021
  • 2021
  • Issue Overview
    2022
    Summary Details
    RESTRICTED
    Title: Issue Overview
    Journal Name: Continuum
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1212/01.con.0000840008.09408.75
    Citation Count: 0
  • Issue Overview
    2022
    Summary Details
    RESTRICTED
    Title: Issue Overview
    Journal Name: Continuum
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1212/01.con.0000892540.33029.c0
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Protective Association of HLA-DRB1*04 Subtypes in Neurodegenerative Diseases Implicates Acetylated Tau PHF6 Sequences
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/01.wnl.0000903160.72715.2d
    Citation Count: 2
  • Summary Details
    OPEN
    Title: Examining the Differences in Biomarkers of Neuronal and Glial Injury Between Autoimmune Neurologic Disease Patients and Healthy Controls
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/01.wnl.0000903096.36040.1d
    Citation Count: 0
  • Summary Details
    OPEN
    Title: A Severe Case of Lupus Cerebritis
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/01.wnl.0000903100.95793.8a
    Citation Count: 1
  • Summary Details
    OPEN
    Title: The ExTINGUISH Trial: A Phase-2B Randomized Placebo-Controlled Trial of Inebilizumab in Anti-NMDA Receptor Encephalitis
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/01.wnl.0000903316.50895.83
    Citation Count: 4
  • Managing Advanced Parkinson Disease
    2021
    Summary Details
    RESTRICTED
    Title: Managing Advanced Parkinson Disease
    Journal Name: Journal of Geriatric Psychiatry and Neurology
    Publisher: SAGE Publications
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1177/08919887211018277
    Citation Count: 9
  • Contextual in situ help for visual data interfaces
    2022
    Summary Details
    RESTRICTED
    Title: Contextual in situ help for visual data interfaces
    Journal Name: Information Visualization
    Publisher: SAGE Publications
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1177/14738716221120064
    Citation Count: 8
  • Summary Details
    OPEN
    Title: Caregiver-Reported Burden in RE-KINECT: Data From a Prospective Real-World Tardive Dyskinesia Screening Study
    Journal Name: Journal of the American Psychiatric Nurses Association
    Publisher: SAGE Publications
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1177/10783903211023565
    Citation Count: 17
  • Summary Details
    RESTRICTED
    Title: ECTRIMS 2021 – ePoster
    Journal Name: Multiple Sclerosis Journal
    Publisher: SAGE Publications
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1177/13524585211044667
    Citation Count: 0
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.